1-aminocyclohexane derivatives for the treatment of hearing loss

Abstract

The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

The invention claimed is: 
     
       1. A method of treating hearing loss in a subject in need thereof, comprising oral administration of a 1-aminocyclohexane derivative selected from the group consisting of neramexane and pharmaceutically acceptable salts thereof, wherein the 1-aminocyclohexane derivative is administered at a dose of about 50 mg/day, and wherein treatment results in alleviation of at least one symptom of hearing loss. 
     
     
       2. The method of  claim 1 , wherein the hearing loss is selected from mild hearing loss, moderate hearing loss, severe hearing loss, profound hearing loss, and deafness. 
     
     
       3. The method of  claim 1 , wherein the hearing loss is selected from acoustic trauma, noise-induced hearing loss, sensorineural hearing loss, mixed hearing loss, unspecified hearing loss, ototoxic hearing loss, drug-induced hearing loss, environmental chemicals-induced hearing loss, cancer-induced hearing loss, surgical-induced hearing loss, radiation-induced hearing loss, infection-induced hearing loss, sudden (idiopathic) hearing loss, auditory processing disorder, and presbycusis. 
     
     
       4. The method of  claim 1 , wherein the 1-amino-alkylcyclohexane derivative is neramexane mesylate. 
     
     
       5. The method of  claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered once a day, twice a day (b.i.d.), or three times a day. 
     
     
       6. The method of  claim 5 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered twice a day. 
     
     
       7. The method of  claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered in an immediate release formulation. 
     
     
       8. The method of  claim 1 , wherein neramexane or a pharmaceutically acceptable salt thereof is administered in a modified release formulation. 
     
     
       9. A method of treating hearing loss in a subject in need thereof, comprising oral administration a 1-aminocyclohexane derivative selected from the group consisting of neramexane and pharmaceutically acceptable salts thereof, wherein the 1-aminocyclohexane derivative is administered at a dose of about 50 mg/day, and an additional pharmaceutical agent which has been shown to be effective in treating hearing loss, wherein treatment results in alleviation of at least one symptom of hearing loss. 
     
     
       10. The method of  claim 9 , wherein the 1-amino-alkylcyclohexane derivative is neramexane mesylate.